New study to prevent type 1 diabetes planned for Diamyd Medical’s diabetes vaccine

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that a new study is planned for the Diamyd® diabetes vaccine that will comprise 80 children with high risk of presenting with type 1 diabetes. The aim is to test whether the diabetes vaccine can prevent or delay the onset in the children. To increase the possibilities of demonstrating efficacy for Diamyd®, a decision has also been taken to keep the ongoing prevention study DiAPREV-IT intact and blinded until all 50 children involved have been monitored for five years, toward the end of 2016. Thus far, 14 children have been